The Wave 1 gene therapy trial involves the CF gene delivered by liposomes. Trial dosing is likely to finish around June, with results hopefully announced in October.

The Wave 2 product appears to be a more effective form of gene therapy. This involves a CF gene delivered by a virus. Trials will hopefully start early 2017.

Click on the title to read more


CFTR Modulators currently help multiple organs by increasing the function of the CFTR protein.

Gene Therapy helps the lungs with a less frequent medication, but is further behind in terms of trial development.

In the future could gene therapy be used in conjunction with CFTR modulators?